Topic: Exploring Mechanisms of Drug Resistance in Cancer Using Multi-omics and Tumor Immune Microenvironment

As research in oncology progresses, it is increasingly recognized that cancer is a complex disease involving multiple systemic factors. Mono-targeted drug therapies alone often fail to achieve ideal clinical outcomes. Therefore, utilizing multi-omics technologies to systematically study tumors has become an important approach in cancer research. Concurrently, there is a growing recognition of the significance of the tumor microenvironment (TME), especially the tumor immune microenvironment (TIME), in cancer initiation and progression. An in-depth analysis of how the TIME affects tumor drug sensitivity is pivotal for devising new combination therapies to overcome drug resistance.

This Special Issue will focus on elucidating the role of TIME in tumor drug resistance using multi-omics technologies. We welcome submissions of original research, reviews, opinions, and perspectives relevant to this Special Issue, including but not limited to:
1. Analyzing immune cell composition and its relationship with drug resistance in tumor samples using single-cell sequencing/spatial transcriptomics;
2. Constructing predictive models of drug resistance by integrating multi-omics data and the TIME;
3. Exploring molecular mechanisms of drug resistance to cancer therapies such as chemotherapy, targeted therapy, and immunotherapy using multi-omics;
4. Developing and validating therapeutic tolerance prediction models and early warning mechanisms based on multi-omics and machine learning;
5. Investigating novel mechanisms related to tumor drug resistance using multi-omics data from in vitro, in vivo, cancer stem cell, and 3D culture models.

Drug resistance, multi-omics, tumor immune microenvironment

1 Nov 2024